Atezolizumab for the treatment of breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Atezolizumab for the treatment of breast cancer

Published:2018-05-04 Issue:5 Volume:18 Page:595-603
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Basile Debora¹,Pelizzari Giacomo¹,Vitale Maria Grazia¹,Lisanti Camilla¹,Cinausero Marika¹,Iacono Donatella²,Puglisi Fabio¹³

Affiliation:

1. School of Medical Oncology, Department of Medicine, University of Udine, Udine, Italy

2. Department of Oncology, University Hospital of Udine, Udine, Italy

3. Department of Clinical Oncology, IRCCS CRO Aviano National Cancer Institute, Aviano (PN), Italy

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2018.1469619

Reference53 articles.

1. Cancer statistics, 2017

2. Active Immunotherapy

3. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

4. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

5. Antagonists of PD-1 and PD-L1 in Cancer Treatment

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus;Frontiers in Immunology;2024-08-12

2. Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment;Current Drug Delivery;2024-08

3. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review);International Journal of Oncology;2023-06-12

4. Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer;International Immunopharmacology;2022-12

5. Insights into the therapeutic potential of histone deacetylase inhibitor/immunotherapy combination regimens in solid tumors;Clinical and Translational Oncology;2022-01-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3